TwinStrand Biosciences Analysis: $67M Raised
What is TwinStrand Biosciences?
TwinStrand Biosciences specializes in Duplex Sequencing technology, which significantly reduces sequencing error rates from 1-in-100 to 1-in-10 million. Their proprietary biochemistry and cloud-based informatics enable the detection of low-frequency variants, making it suitable for applications in measurable residual disease and mutation monitoring. The company collaborates with various research institutions to enhance mutagenicity assessments and regulatory decision-making.
Location
3131 Elliott Ave #750, Seattle, WA 98121, United States
Employees
51-200
Founded
2015
Funding Status
Growth
Product Features & Capabilities
- AML Assay
- Mutagenesis Assay
- Nitrosamine Testing
- Mutagenesis Testing
Use Cases
Measure minimal residual disease in acute myeloid leukemia; Identify mutations with high resolution; Monitor cellular immunotherapy effectiveness; Assess mutagenicity in regulatory studies; Detect low-frequency variants in genomic research
Other Considerations
Initiated regulatory approval process for Duplex Sequencing assays; Collaborated with Health Canada for inter-laboratory validation studies; Published research demonstrating technology's effectiveness in mutagenicity assessments
See something that needs updating? Suggest edits to this profile.